Taken together, these results demonstrate the therapeutic capability of C11 in mitigating exercise-induced arrhythmias associated with the pathological overactivation of β1ARs in the heart and underscore its potential as a new class of drug to block the β1AR in disease states. This evidence concerns the gene ADRB1 and cardiac arrhythmia.